GBA W378G-correction/2890, 2890-iso
CBIGi002-A-1
General
Cell Line |
|
| hPSCreg name | CBIGi002-A-1 |
| Cite as: | CBIGi002-A-1 (RRID:CVCL_C0K7) |
| Alternative name(s) |
GBA W378G-correction/2890, 2890-iso
|
| Cell line type | Human induced pluripotent stem cell (hiPSC) |
| Similar lines |
CBIGi002-A (2890 (GBA W378G, heterozygous), 2890) Donor's gene variants: GBA, GBA Donor diseases: Parkinson Disease EDi001-A-2 (AST23-1KO-3, AST22-1KO-3, AST-23_SCAKO Clone 3, AST-22_SNCAKO Clone 3) Donor's gene variants: SNCA, SNCA, SNCA, SNCA Donor diseases: Parkinson disease EDi001-A-3 (AST23_SNCAKO Clone 1, AST22-1KO-1, AST23-1KO-1, AST22_SNCAKO Clone 1) Donor's gene variants: SNCA, SNCA, SNCA, SNCA Donor diseases: Parkinson disease EDi001-A-4 (AST22-2KO-6, AST23_SNCAKO Clone 6, AST22_SNCAKO Clone 6, AST23-2KO-6) Donor's gene variants: SNCA, SNCA, SNCA, SNCA Donor diseases: Parkinson disease STBCi004-B-1 (SFC832-03-06 LRRK2WT/WT C47) Donor's gene variants: LRRK2 Donor diseases: Parkinson disease |
| Last update | 14th April 2022 |
| Notes | Isogenic control for CBIGi002-A. |
| User feedback | |
Provider |
|
| Generator | Clinical Biospecimen Imaging and Genetic (C-BIG) Repository (CBIG) |
| Derivation country | Canada |
External Databases |
|
| BioSamples | SAMEA13204586 |
| Cellosaurus | CVCL_C0K7 |
| Wikidata | Q112929371 |
General Information |
|
| Publications | |
| * Is the cell line readily obtainable for third parties? |
Yes Research use: allowed
Clinical use: not allowed
Commercial use: not allowed
|
| Subclone of | |
Donor Information
General Donor Information |
|
| Sex | female |
Phenotype and Disease related information (Donor) |
|
| Diseases | A disease was diagnosed.
|
External Databases (Donor) |
|
| BioSamples | SAMEA13200845 |
Ethics
Also have a look at the ethics information for the parental line
CBIGi002-A
.
| For generation of the cell line, who was the supplier of any recombined DNA vectors or commercial kits used? |
hIPSC Derivation
General |
|
|
The source cell information can be found in the parental cell line
CBIGi002-A.
|
|
Reprogramming method |
|
| Vector type | Non-integrating |
| Vector | Episomal |
Vector free reprogramming |
|
Other |
|
| Derived under xeno-free conditions |
Unknown |
| Derived under GMP? |
Unknown |
| Available as clinical grade? |
Unknown |
Culture Conditions
| Surface coating | Matrigel/Geltrex |
| Feeder cells |
No |
| Passage method |
Enzyme-free cell dissociation
Gentle Cell Dissociation Reagent
|
| Medium |
mTeSR™ 1
|
Characterisation
Analysis of Undifferentiated Cells
| Marker | Expressed | Immunostaining | RT-PCR | Flow Cytometry | Enzymatic Assay | Expression Profiles |
| NANOG |
Yes |
|
||||
| POU5F1 (OCT-4) |
Yes |
|
||||
| SSEA-4 |
Yes |
|
||||
| TRA 1-60 |
Yes |
|
Differentiation Potency
Microbiology / Virus Screening |
|
| Mycoplasma | Negative |
Genotyping
Karyotyping (Cell Line) |
|
| Has the cell line karyotype been analysed? |
Yes
46,XX
Karyotyping method:
G-Banding
|
Other Genotyping (Cell Line) |
|
Genetic Modification
| Genetic modifications not related to a disease |
|
Login to share your feedback, experiences or results with the research community.